Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Barlati is active.

Publication


Featured researches published by S. Barlati.


Intervirology | 1974

Different stages of transformation of Rous virus-infected cells evidenced by methylene blue staining.

S. Barlati; Cécile Kryceve

Foci of Rous cells produced by various Rous sarcoma virus (RSV) strains stain with methylene blue and can be distinguished from the background of unstained density-inhibited normal cells. RSV-infected


Protides of the biological fluids | 1982

Role of Fibronectin Degradation Products on Cellular Transformation

S. Barlati; G. De Petro; Tapio Vartio; Antti Vaheri

Abstract Plasminolytic fragments of Fibronectin but not of Fibrinogen have a potent transformation enhancing activity and may act, in vivo , as “natural tumor promoters”.


Intervirology | 1973

Activation of DNA Polymerase of Murine Leukemia Virus by Rifamycin Derivatives

S. Barlati; Agnese Brega; Luigi G. Silvestri

Some rifamycin derivatives are strong inhibitors of DNA polymerase of RNA tumor viruses. However, when this activity is assayed in intact virions, in the presence of limiting concentrations of detergent, some concentrations of these drugs stimulate enzyme activity. Activation of the polymerase was achieved even in the absence of detergent in the presence of appropriate concentrations of these antibiotics. This property seems to be restricted to rifamycin derivatives possessing bulky non-polar side chains which give the molecule a ‘detergent-like’ character. It is not clear whether this property is also responsible for inhibition of the viral polymerase.


Journal of Hepatology | 2011

216 MIR-100 IS DOWNREGULATED FROM EARLY STAGES OF HEPATOCARCINOGENESIS AND CORRELATES WITH OVEREXPRESSION OF ITS TARGET PLK1

Annalisa Petrelli; A. Perra; K. Schernhuber; Alessandro Salvi; Cristina Migliore; Elena Ghiso; Anna Benetti; Giovanna M. Ledda-Columbano; S. Barlati; Nazario Portolani; G. de Petro; Amedeo Columbano; Silvia Giordano

available kits. DNA samples were typed for SNPs: −1195 G>A of COX-2, −308 G>A of TNF-a, +936 C>T of VEGF-A and −174 G>C of IL-6 genes. RFLP-PCR method was used to type the SNPs. sIL-6 were dosed with a commercially available ELISA kit. Results: Our data show a statistically significant difference only for the SNP of VEGF-A +936 C>T between HCC and LC patients (P = 0.039). sIL-6 were higher in G/G compared to C/C genotypes in HCC (z = 2; P = 0.04) and G/G vs G/C (z = 1.8; P < 0.03). sIL-6 in G carriers (G/G+G/C) were higher in HCC 4.8 (0.2–17.5) vs LC patients 2.2 (0.07–11.5) (z = 2.8; P = 0.004). sIL-6 in HCC correlated with G carriers (G/G+G/C) (r = 0.25, P = 0.05). A positive correlation was found between sIL-6 levels and some liver function tests both in LC and in HCC. Conclusions: Our results show that C allele carriers in VEGF-A gene are more frequent in HCC vs LC, and confirm the association between the G carriers in IL-6 gene and higher sIL-6, suggesting that these genetic factors could contribute to the development of HCC.


Protides of the biological fluids | 1984

Transformation-Enhancing Activity Present in the Plasma of Cancer Patients Binds to Gelatin

G. De Petro; Tapio Vartio; Antti Vaheri; S. Barlati

Abstract Transformation-enhancing activity (TEF activity) present in the plasma cryopre-cipitates (cryo) of cancer patients binds to gelatin. The gelatin-binding (GB) fraction from TEF positive plasma cryos contains high levels of high molecular weight fibronectin (FN) fragments, almost absent in the gelatin-nonbinding (GNB) fraction. A higher concentration of tissue-plasminogen activator (t-PA) is also present in the GB as compared to the GNB fraction.


Proceedings of the National Academy of Sciences of the United States of America | 1981

Transformation-enhancing activity of gelatin-binding fragments of fibronectin

G De Petro; S. Barlati; Tapio Vartio; Antti Vaheri


Invasion & Metastasis | 1983

Fibronectin and its proteolytic fragments. Potential as cancer markers.

Vartio T; Vaheri A; De Petro G; S. Barlati


International Journal of Cancer | 1983

Transformation-enhancing activity in plasma of tumor patients: Relationship with fibronectin fragments

Giuseppina De Petro; S. Barlati; Tapio Vartio; Antti Vaheri


Biochemical Journal | 1983

Monoclonal antibody against the N-terminal end of human plasma fibronectin.

Tapio Vartio; Eeva-Marjatta Salonen; G De Petro; S. Barlati; Vincenzo Miggiano; Christian Stähli; Giuseppe Virgallita; B Takács; Antti Vaheri


International Journal of Cancer | 1976

Transformation‐enhancing factor(s) produced by virustransformed and established cells

C. Krycéve; S. Barlati

Collaboration


Dive into the S. Barlati's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge